Glycemic Response in Adults With Type 2 Diabetes

Glycemic Control Clinical Trial

Official title:

Postprandial Glycemic Response to a Diabetes-Specific Formula and Oatmeal in Adults With Type 2 Diabetes

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05166200
• Other study ID #: BL59
• Status: Completed
• Phase: N/A
• Start date: March 11, 2022
• Est. completion date: June 20, 2022

Study information

• Verified date: June 2022
• Source: Abbott Nutrition
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a randomized, controlled, crossover study to compare the effects of two treatments on postprandial glucose in adults with type 2 diabetes.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 26
• Est. completion date: June 20, 2022
• Est. primary completion date: June 20, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 21 Years to 75 Years

Eligibility

Inclusion Criteria:

• Age = 21 and = 75 years

• Participant has type 2 diabetes as evidenced by use of oral antihyperglycemic medication(s) with constant dose for at least two months prior to screening and baseline visit. Participant is able to maintain medication number, type and dose throughout the duration of study.

• Participant with a BMI > 18.5 and = 40.0 kg/m2

• Participant is weight stable for the two months prior to the screening visit.

• Male or a non-pregnant, non-lactating female, at least 6 weeks postpartum prior to screening visit.

• If the participant is on a chronic medication such as an anti-hypertensive, lipid-lowering, thyroid medication or hormone therapy, the dosage must be constant for at least two months prior to screening and baseline visit. Participant is able to maintain medication number, type and dose throughout the duration of study.

• Participant is willing to follow protocol as described, including consumption of study product per protocol and completing any forms needed throughout the study.

• Participant has at least a two-week washout period between completion of a previous research study that required ingestion of any study food or drug and Visit 2 when assigned study product is consumed.

• Participant is willing to refrain from taking non-study diabetes-specific formulas over the entire course of the study.

• Participant has voluntarily signed and dated an Informed Consent Form (ICF), approved by an Independent Ethics Committee/Institutional Review Board (IEC/IRB) prior to any participation in the study.

Exclusion Criteria:

• Participant has a screening HbA1c level < 7% or = 10%.

• Participant uses exogenous insulin or GLP-1 agonists or DPP-4 inhibitors for glucose control.

• Participant has confirmed type 1 diabetes and/or had history of diabetic ketoacidosis.

• Participant has current infection, inpatient surgery or received systemic corticosteroid treatment in the last 3 months; or received antibiotics in the last 3 weeks.

• Participant has active malignancy.

• Participant has significant cardiovascular event within 6 months prior to study entry or history of congestive heart failure.

• Participant has end stage organ failure or was post organ transplant.

• Participant has a history of renal disease or severe gastroparesis.

• Participant has current hepatic disease.

• Participant has had bariatric surgery including gastric balloon; history of gastrointestinal disease or intestinal surgery that can interfere with consumption or digestion or absorption of study product.

• Participant has a chronic, contagious, infectious disease, such as active tuberculosis, Hepatitis A, B or C, or HIV.

• Participant has eating disorder, severe dementia or delirium, history of significant neurological or psychiatric disorder, alcoholism, substance abuse or other conditions that may interfere with study product consumption or compliance with study protocol procedures.

• Participant is taking any herbals, dietary supplements, or medications, other than allowed anti-hyperglycemic medications, during the past four weeks prior to screening visit that could profoundly affect blood glucose or appetite.

• Participant uses diabetes-specific formula(s) defined as more than one eating occasion per week in the last three months.

• Participant has clotting or bleeding disorders. The use of Plavix® or a similar anticoagulant drug with no reported difficulty during blood draws is allowed and participant is able to maintain medication number, type and dose throughout the duration of study.

• Participant participates in another study that has not been approved as a concomitant study by AN.

• Participant has an allergy or intolerance to any ingredient in the study product, as reported by the participant.

Related Conditions & MeSH terms

• Glycemic Control

Intervention

Other:
• Experimental Formula
Diabetes-specific study formula
• Test Meal
Instant oatmeal

Locations

Country	Name	City	State
United States	Great Lakes Clinical Trials, LLC	Gurnee	Illinois
United States	Finlay Medical Research	Miami	Florida

Sponsors (1)

Lead Sponsor	Collaborator
Abbott Nutrition

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Glucagon-Like Peptide-1 (GLP-1) positive area under the curve	Calculated from blood samples	0 to 240 minutes
Other	Glucagon-Like Peptide-1 (GLP-1) peak value	Calculated from blood samples	0 to 240 minutes
Other	Glucagon-Like Peptide-1 (GLP-1) peak time	Calculated from blood samples	0 to 240 minutes
Other	Glucagon-Like Peptide-1 (GLP-1) concentrations	Calculated from blood samples	0 to 240 minutes
Other	Appetite Questionnaire	5 Visual analog scales; Including Score from Not al All to Extremely or Nothing to Most	Study Day 1 to Study Day 7
Other	Sensory Questionnaire	10 sensor and hedonic questions; Up to 9-Point Likert Scale questions including Dislike Extremely to Like Extremely or Much too to Much Less or Not at all to Extremely	Study Day 1 to Study Day 7
Primary	Glucose positive area under the curve (AUC)	Calculated from blood samples	0 to 240 minutes
Secondary	Insulin positive area under the curve (AUC)	Calculated from blood samples	0 to 240 minutes
Secondary	Insulin peak value	Calculated from blood samples	0 to 240 minutes
Secondary	Glucose peak value	Calculated from blood samples	0 to 240 minutes
Secondary	Insulin peak time	Calculated from blood samples	0 to 240 minutes
Secondary	Glucose peak time	Calculated from blood samples	0 to 240 minutes
Secondary	Insulin Concentrations	Calculated from blood samples	0 to 240 minutes
Secondary	Glucose Concentrations	Calculated from blood samples	0 to 240 minutes